ClinicalTrials.gg
Status unknownNCT02887625Updated Sep 2, 2016

Exenatide Plus Pioglitazone Versus Insulin in Poorly Controlled T2DM

An interventional study of Pioglitazone plus exenatide and insulin glargine and insulin aspart in Type 2 Diabetes, sponsored by Dr. Muhammad Abdulghani. Status unknown at 1 site in Qatar. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-09-02.

Sponsored by Dr. Muhammad Abdulghani · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Aug 2016), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
410
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 122 studies testing pioglitazone in Diabetes Mellitus, Type 2 — 7 open to participants now, 8 under way, 1 of them phase 3. Pioglitazone · Diabetes Mellitus, Type 2.

Planned enrollment
26th of 122
410 · median 103
Started
2015
with 2 others
No phase
17 of 122
1 open now
Registered
98th of 122
by date

Among the 122 studies testing pioglitazone in Diabetes Mellitus, Type 2, this one is the 26th largest by planned enrollment, is one of 3 that started in 2015, is one of 17 with no phase, and was the 98th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

7 of the 122 studies testing pioglitazone in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About pioglitazone

Pioglitazone: first FDA approval 1999 (ACTOS), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 122 studies testing pioglitazone in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

To compare efficacy, safety and durability of combination therapy with pioglitazone plus GLP-1 RA versus basal bolus insulin in poorly controlled T2DM patients on metformin plus sulfonylurea

Read the detailed description

poorly controlled (HbA1c >7.5%) T2DM patients (18-75 years of age) on maximal/near maximal dose of sulfonylurea plus metformin who otherwise are healthy will be randomized to receive:

  1. exenatide weekly injection (2 mg/week)
  2. glargine insulin plus insulin aspart which will be titrated to maintain HbA1c \<7.0%
03

Conditions studied

  • Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • T2DM poorly controlled ( >7.5%) on metformin (>1700 mg/day) plus sulfonylurea

Exclusion criteria

Exclusion Criteria:

  • type 1 diabetes (T1DM) patients receiving therapy with pioglitazone, GLP-1 RA and insulin abnormal kidney, liver or heart function patients with
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
410 participants (estimated)

Study arms

  • Experimental
    Combination Therapy

    pioglitazone (actos) 30 mg per day and exenatide (bydureon) 2 mg per week

    Drug: Pioglitazone plus exenatide

  • Active comparator
    Insulin Therapy

    insulin glargine (lantus) will be started every morning and the dose will be weekly increase to achieve fasting plasma glucose (FPG) \<110 mg/dl. and Aspart insulin will be started before meals and the dose is adjusted to maintain HbA1c \<7.0% and postprandial plasma glucose (PPG) \<140 mg/dl

    Drug: insulin glargine and insulin aspart

Interventions

  • DrugPioglitazone plus exenatide

    Drug pages: Pioglitazone · Exenatide

    pioglitazone will be started at 30 mg/day and bydureon at 2 mg/week

    Also known as: actos and bydureon

  • Druginsulin glargine and insulin aspart

    Drug pages: Insulin Glargine · Insulin Aspart

    the dose will be escalated to maintain HbA1c \<7.0%

    Also known as: lantus

06

What researchers measure

Primary outcomes

  1. HbA1c

    difference in HbA1c between the two treatment groups will be compared at 1 and at 3 years to determine efficacy and durability of each treatment

    Time frame: 3 years

Secondary outcomes

  1. percentage of patients who achieve HbA1c <7.0% and <6.5% at 1 year and at 3 years

    Time frame: 3 years

  2. hypoglycemia rate

    will be measured as absolute event rate per patient year of follow up

    Time frame: 3 years

  3. change in the FPG

    change in FPG from time zero to 1 year and from baseline to 3 years in each treatment group

    Time frame: 3 years

  4. change in body weight

    change in body weight from time zero to 1 year and to 3 years in each treatment group

    Time frame: 3 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Abdul-Ghani M, Migahid O, Megahed A, Adams J, Triplitt C, DeFronzo RA, Zirie M, Jayyousi A. Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study. Diabetes Care. 2017 Mar;40(3):325-331. doi: 10.2337/dc16-1738. Epub 2017 Jan 17. Erratum In: Diabetes Care. 2017 Aug;40(8):1134. doi: 10.2337/dc17-er08d. PubMed 28096223 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2015, a primary completion of May 2017 and a completion of May 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2016
First posted
Sep 2, 2016
Start
Feb 2015
Primary completionEst.
May 2017
CompletionEst.
May 2017
Last update
Sep 2, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02887625
Lead sponsor
Dr. Muhammad Abdulghani
Responsible party
Dr. Muhammad Abdulghani (Professor of Medicine, Hamad Medical Corporation) — Sponsor-investigator
First posted
Sep 2, 2016
Start date
Feb 2015
Primary completion
May 2017 (estimated)
Completion
May 2017 (estimated)
Last update
Sep 2, 2016

Study contacts

Muhammad Abdul-Ghani, MD, PhD
Contact
ABDULGHANI@UTHSCSA.EDU
44391208
Amin Jayyousi, MD
Contact
ajayyousi@hamad.qa
55530236
Amin Jayyousi, MD
principal investigator · HMC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pioglitazone · Exenatide

Start the discussion